OBJECTIVE: With rising @entity28 , it is becoming increasingly difficult to distinguish between @entity1723 ( @entity1723 ) and @entity2175 ( @entity2175 ) in young adults. There has been substantial recent progress in identifying the contribution of common genetic variants to @entity1723 and @entity2175 . We aimed to determine whether a score generated from common genetic variants could be used to discriminate between @entity1723 and @entity2175 , and also to predict @entity1720 in young adults with @entity6 . RESEARCH DESIGN AND METHODS: We developed genetic risk scores (GRSs) from published @entity1723 - and @entity2175 -associated variants. We first tested whether the scores could distinguish clinically defined @entity1723 and @entity2175 from the Wellcome Trust Case Control Consortium (WTCCC, n = 3,887). We then assessed if the @entity1723 GRS correctly classified young adults (diagnosed at 20-40 years of age, the age group with the most diagnostic difficulty in clinical practice; n = 223) who progressed to @entity1720 <3 years from diagnosis. RESULTS: In the WTCCC, the @entity1723 GRS, based on 30 @entity1723 -associated risk variants, was highly discriminative of @entity1723 and @entity2175 (area under the curve [AUC] 0.88 [95% CI 0.87-0.89]; P < 0.0001), and the @entity2175 GRS added little discrimination (AUC 0.89). A @entity1723 GRS >0.280 (>50th centile in those with @entity1723 ) is indicative of @entity1723 (50% sensitivity, 95% specificity). A low @entity1723 GRS (<0.234, <5th centile @entity1723 ) is indicative of @entity2175 (53% sensitivity, 95% specificity). Most discriminative ability was obtained from just nine single nucleotide polymorphisms (AUC 0.87). In young adults with @entity6 , @entity1723 GRS alone predicted @entity1720 (AUC 0.87 [95% CI 0.82-0.92]; P < 0.0001). @entity1723 GRS, autoantibody status, and clinical features were independent and additive predictors of @entity1720 (combined AUC 0.96 [95% CI 0.94-0.99]; P < 0.0001). CONCLUSIONS: A @entity1723 GRS can accurately identify young adults with @entity6 who will require insulin treatment. This will be an important addition to correctly classifying individuals with @entity6 when clinical features and autoimmune markers are equivocal.

A Type 1 @entity6 Genetic Risk Score Can Aid Discrimination Between Type 1 and Type 2 XXXX in Young Adults.

@entity2175 :: ('MESH:D003924', 'Disease') :: ['type 2 diabetes', 'T2D'] @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes'] @entity28 :: ('MESH:D009765', 'Disease') :: ['obesity'] @entity1723 :: ('MESH:D003922', 'Disease') :: ['T1D', 'type 1 diabetes'] @entity1720 :: ('MESH:D007333', 'Disease') :: ['severe insulin deficiency', 'progression to insulin deficiency']
@entity6 :: (MESH:D003920,Disease) :: ['Diabetes']
